Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02300441
Other study ID # HI-VISION Pilot Study
Secondary ID
Status Completed
Phase
First received October 20, 2014
Last updated April 20, 2018
Start date September 2014
Est. completion date September 2015

Study information

Verified date March 2016
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective cohort pilot study of non-cardiac patients to determine the feasibility of recruiting 150 patients to undergo postoperative continuous hemodynamic monitoring for up to 3 days.


Description:

Patient will start wearing the Philips' hemodynamic and ECG monitor in the Post Anaesthesia Care Unit (PACU). This device will continuously measure heart rate, pulse oxymetry, and ST-segments. The device will measure blood pressure every hour from 7 am to 10 pm and every 2 hours from 10 pm to 7 am.

Patients will have postoperative Troponin I monitoring and telephone follow-up at 30 days postop.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date September 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria: We will enroll patients aged 45 years or older undergoing noncardiac surgery who fulfilled 2 or more of the following risk factors:

- History of coronary artery disease

- History of stroke or transient ischemic attack (TIA)

- History of hypertension

- History of diabetes

- History of peripheral vascular disease

- History of congestive heart failure

- Preoperative creatinine > 175 umol/L

- A planned admission for =48 hours

- Patients receiving a general or regional anesthetic

Exclusion Criteria:

- Patients unable to provide informed consent.

- Patients who undergo procedure performed under infiltrative or topical anesthesia.

- Patients previously enrolled in the HI-VISION Study.

- Patients who refuse 30-day follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ECG, blood pressure and oximetry


Locations

Country Name City State
Canada Juravinski Hospital Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
McMaster University Hamilton Health Sciences Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Postoperative Pain (association between postoperative pain intensity and myocardial ischemia, nonfatal myocardial infarction, and cardiac mortality) To determine the association between postoperative pain intensity and myocardial ischemia, nonfatal myocardial infarction, and cardiac mortality. 10 months
Primary Hypotension and Hypoxemia (baseline patterns and frequencies) To identify baseline patterns and frequencies of hypotension and hypoxemia. 10 months
Secondary Myocardial Ischemia (association between myocardial ischemia detected by the algorithm implemented by MX40 with Troponin I) To determine the association between myocardial ischemia detected by the algorithm implemented by MX40 with Troponin I. 10 months
Secondary Myocardial Ischemia (delay in detecting myocardial ischemia based on MX40 monitoring versus Troponin I monitoring) To determine the delay in detecting myocardial ischemia based on MX40 monitoring versus Troponin I monitoring. 10 months
Secondary Myocardial Ischemia (number of patients with missed clinically important hypotension, bradycardia, and hypoxia based on routine monitoring in clinical practice versus remote, automated, non-invasive hemodynamic monitoring) To determine the number of patients with missed clinically important hypotension, bradycardia, and hypoxia based on routine monitoring in clinical practice versus remote, automated, non-invasive hemodynamic monitoring. 10 months
Secondary Myocardial Ischemia (delay in detecting clinically important hypotension, bradycardia, and hypoxia based on routine monitoring in clinical practice versus remote, automated, non-invasive hemodynamic monitoring.) To determine the delay in detecting clinically important hypotension, bradycardia, and hypoxia based on routine monitoring in clinical practice versus remote, automated, non-invasive hemodynamic monitoring. 10 months